Ahn MJ, Yang J, Yu H, et al. Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTOn phase Ib trial. Presented at: European Lung Cancer Conference; April 13-16, 2016; Geneva, Switzerland. Abstract 1360.
Aisner DL, Sholl LM, Berry LD, et al. The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations-the lung cancer mutation consortium (LCMC2). Clin Cancer Res. 2018;24:1038-1047.
Allen JM, Schrock AB, Erlich RL, et al. Genomic profiling of circulating tumor DNA in relapsed EGFR-mutated lung adenocarcinoma reveals an acquired FGFR3-TACC3 fusion. Clin Lung Cancer. 2017;18:e219-e222.
Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.
Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376:2415-2426.
Dias L, Chabner BA, Lynch TJ Jr, et al. Breaking bad news: a patient’s perspective. Oncologist. 2003;8:587-596.
Ersek JL, Black LJ, Thompson MA, et al. Implementing precision medicine programs and clinical trials in the community-based oncology practice: barriers and best practices. Am Soc Clin Oncol Educ Book. 2017;37:597-606.
Gainor JF, Rizvi H, Aguilar EJ, et al. Response and durability of anti-PD-(L)1 therapy in never or light smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression. Presented at: 2018 ASCO Annual Meeting; June 1-5, 2017; Chicago, IL. Abstract 9011.
Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078-2092.
Gibbons DL, Chow LQ, Kim DW, et al. Efficacy, safety and tolerability of MEDI4736 (durvalumab), a human IgG1 anti-programmed cell death-ligand-1 antibody, combined with gefitinib: a phase I expansion in TKI-naïve patients with EGFR mutant NSCLC. J Thorac Oncol. 2016;11:S79.
Gray SW, Hicks-Courant K, Cronin A, et al. Physicians’ attitudes about multiplex tumor genomic testing. J Clin Oncol. 2014;32:1317-1323.
Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378:2093-2104.
Hwang DH, Garcia EP, Ducar MD, et al. Next-generation sequencing of cytologic preparations: an analysis of quality metrics. Cancer Cytopathol. 2017;125:786-794.
Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology clinical practice guideline update. J Clin Oncol. 2018;36:911-919.
Kehl KL, Landrum MB, Arora NK, et al. Association of actual and preferred decision roles with patient-reported quality of care: shared decision making in cancer care. JAMA Oncol. 2015;1:50-58.
Knepper TC, Bell GC, Hicks JK, et al. Key lessons learned from Moffitt’s molecular tumor board: the clinical genomics action committee experience. Oncologist. 2017;22:144-151.
Komatsubara KM, Sacher AG. Circulating tumor DNA as a liquid biopsy: current clinical applications and future directions. Oncology (Williston Park). 2017;31:618-627.
Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomized, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17:1497-1508.
Lanman RB, Mortimer SA, Zill OA, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLOS One. 2015;10:e0140712.
Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the election of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142:321-346.
Lisberg A, Cummings A, Goldman JW. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC. J Thorac Oncol. 201;13(8):1138-1145.
Lopes G, Wu YL, Kudaba I, et al. Pembrolizumab versus platinum-based chemotherapy as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score ≥ 1%: open-label, phase 3 KEYNOTE-042 study. Presented at: 2018 ASCO Annual Meeting; June 1-5, 2018; Chicago, IL. Abstract LBA4.
Mazieres J, Drilon AE, Mhanna L, et al. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring activating molecular alterations (ImmunoTarget). Presented at: 2018 ASCO Annual Meeting; June 1-5, 2018; Chicago, IL. Abstract 9010.
Merker JD, Oxnard GR, Compton C, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. J Clin Oncol. 2018;36(16):1631-1641.
Miotke L, Lau BT, Rumma RT, et al. High sensitivity detection and quantitation of DNA copy number and single nucleotide variants with single color droplet digital PCR. Anal Chem. 2014;86:2618-2624.
National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. Version 1.2019. October 19, 2018.
Normanno N, Denis Mg, Thress KS, et al. Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer. Oncotarget. 2017;8:12501-12516.
Oshima Y, Tanimoto T, Yuji K, et al. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMA Oncol. 2018;4:1112-1115.
Oxnard GR, Thress K, Paweletz C, et al. Mechanisms of acquired resistance to ACZ9291 in EGFR T790M positive lung cancer. Presented at: 16th World Conference on Lung Cancer; September 8, 2015; Denver, Colorado. Abstract OA 17.17.
Oxnard GR, Thress KS, Alden RS, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol. 2016;34:3375-3382.
Oxnard GR, Hu Y, Mileham KF, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 2018;4:1527-1534.
Personal Genome Diagnostics. PlasmaSELECT-R64. http://www.personalgenome.com/pharma-biotech-companies/liquid-biopsy/. Accessed November 14, 2018.
Piotrowska Z, Thress KS, Mooradian M, et al. MET amplification (amp) as a resistance mechanism to osimertinib. J Clin Oncol. 2017;35:9020-9020.
Piotrowska Z, Nagy R, Fairclough S, et al. Characterizing the genomic landscape of EGFR C797S in lung cancer using ctDNA next generation sequencing. Presented at: 18th World Conference on Lung Cancer; October 15-18, 2017; Yokohama, Japan. Abstract OA 09.01.
Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18:1307-1316.
Ramalingam SS, Yang JC, Lee CK, et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018;36:841-849.
Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823-1833.
Reckamp KL, Melnikova VO, Karlovich C, et al. A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma. J Thorac Oncol. 2016;11:1690-1700.
Ricciuti B, Bagliov S, Paglialunga L, et al. Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Ther Adv Med Oncol. 2017;9:387-403.
Roy-Chowdhuri S, Chen H, Singh RR, et al. Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies. Mod Pathol. 2017;30:499-508.
Rudin C, Cervantes A, Dowlati A, et al. Safety, clinical activity and biomarker results from a phase Ib study of erlotinib plus atezolizumab in advanced NSCLC. J Thorac Oncol. 2017;12:S1302-S1303.
Sequist LV, Wade Goldman J, Wakelee HA, et al. Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). Presented at: 2015 ASCO Annual Meeting; May 29-June 2, 2015; Chicago, IL. Abstract 8001.
Sheikine Y, Rangachari D, McDonald DC, et al. EGFR testing in advanced non-small-cell lung cancer, a mini review. Clin Lung Cancer. 2016;17:483-492.
Socinski MA, Jotte RM, Cappuzzo F, et al. Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. Presented at: 2018 ASCO Annual Meeting; June 1-5, 2018; Chicago, IL. Abstract 9002.
Tafe LJ. Molecular mechanisms of therapy resistance in solid tumors: chasing “moving” targets. Virchows Archiv. 2017;471:155-164.
Thompson G. Humanizing cancer care: the patient perspective. Oncol Nurse. 2018;11:4125.
Thress KS, Brant R, Carr TH, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291.
van der Velden DL, van Herpen CM, van Laarhoven HW, et al. Molecular tumor boards: current practice and future needs. Ann Oncol. 2017;28:3070-3075.
Wakelee HA, Gadgeel SM, Wade J, et al. Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non small cell lung cancer (NSCLC) patients (pts) treated with rociletinib. Presented at: 2016 ASCO Annual Meeting; June 3-7, 2016; Chicago, IL. Abstract 9001.
Weerts MJA, Timmermans EC, Vossen RHAM. Sensitive detection of mitochondrial DNA variants for analysis of mitochondrial DNA-enriched extracts from frozen tumor tissue. Sci Rep. 2018;8:2261.
Wu YL, Zhang L, Kim DW, et al. Phase Ib/II study of capmatinib plus gefitinib after failure of epidermal growth factor receptor inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer. J Clin Oncol. 2018;36:3101-3109.
Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2014;19:2240-2247.

CME / ABIM MOC

Finding the Patient Perspective: Molecular Testing in Advanced NSCLC

Authors: Christina Lockwood, PhD, DABCC, DABMGG; Eric H. Bernicker, MD; Lynette Marie Sholl, MD; Donald Stranathan
CME / ABIM MOC Released: 12/17/2018
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 12/17/2019, 11:59 PM EST

Target Audience and Goal Statement

This activity is intended for pathologists, oncologists, and pulmonologists.

The goal of this symposium is to provide pathologists with the latest information and best practices for molecular testing of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) throughout the continuum of disease while keeping in mind the patient's perspective.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Updated guidelines and evidence on biomarker tests that should be ordered to adequately characterize NSCLC
Have greater competence related to
- Strategies improving time to appropriate treatment in patients with newly diagnosed or progressive EGFR-mutated NSCLC, including use of liquid biopsies, next-generation sequencing, and reflex testing
- How biomarker testing results can be used to guide treatment selection in patients with EGFR-mutated NSCLC in the first, second, and third line

Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Speakers

Christina Lockwood, PhD, DABCC, DABMGG

Associate Professor
Department of Laboratory Medicine
Director
Genetics and Solid Tumor Diagnostics Laboratory
University of Washington
Seattle, Washington

Disclosures

Disclosure: Christina Lockwood, PhD, DABCC, DABMGG, has disclosed no relevant financial relationships.

Eric H. Bernicker, MD

Associate Professor of Clinical Medicine
Weill Cornell Medical College
Associate Professor of Clinical Medicine
Houston Institute for Academic Medicine
Thoracic Medical Oncology
Medical Director, Clinical Trials Office
Houston Methodist Cancer Center
Houston, Texas

Disclosures

Disclosure: Eric H. Bernicker, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; AstraZeneca Pharmaceuticals LP; Guardant Health

Lynette Marie Sholl, MD

Associate Professor
Harvard Medical School
Associate Pathologist
Brigham and Women's Hospital
Boston, Massachusetts

Disclosures

Disclosure: Lynette Marie Sholl, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Foghorn Therapeutics

Donald Stranathan

Lung Cancer Survivor/Advocate
Santa Rosa, California

Disclosures

Disclosure: Donald Stranathan has disclosed no relevant financial relationships.

Editor

Elaine Hamarstrom, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Elaine Hamarstrom, PhD, has disclosed no relevant financial relationships.

Chelsey Goins

Freelance Writer

Disclosures

Disclosure: Chelsey Goins has disclosed no relevant financial relationships.

AMP Reviewer

Lucia Barker, PhD

Association for Molecular Pathology

Disclosures

Disclosure: Lucia Barker, PhD, has disclosed no relevant financial relationships.

CME Reviewer

Amy Bernard, MS, BSN, RN-BC, CHCP

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Ipsen BioPharmaceuticals

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC

Finding the Patient Perspective: Molecular Testing in Advanced NSCLC

Authors: Christina Lockwood, PhD, DABCC, DABMGG; Eric H. Bernicker, MD; Lynette Marie Sholl, MD; Donald StranathanFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 12/17/2018

Valid for credit through: 12/17/2019, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this symposium is to provide pathologists with the latest information and best practices for molecular testing of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) throughout the continuum of disease while keeping in mind the patient's perspective.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CME / ABIM MOC Information Download Slides

Q & A

Print
Like Tweet

Presented through a collaboration between The Association for Molecular Pathology (AMP) and Medscape Education.

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Speakers

Christina Lockwood, PhD, DABCC, DABMGG

Eric H. Bernicker, MD

Lynette Marie Sholl, MD

Donald Stranathan

Editor

Elaine Hamarstrom, PhD

Chelsey Goins

AMP Reviewer

Lucia Barker, PhD

CME Reviewer

Amy Bernard, MS, BSN, RN-BC, CHCP

CME / ABIM MOC

Finding the Patient Perspective: Molecular Testing in Advanced NSCLC

Target Audience and Goal Statement

Disclosures

Speakers

Christina Lockwood, PhD, DABCC, DABMGG

Eric H. Bernicker, MD

Lynette Marie Sholl, MD

Donald Stranathan

Editor

Elaine Hamarstrom, PhD

Chelsey Goins

AMP Reviewer

Lucia Barker, PhD

CME Reviewer

Amy Bernard, MS, BSN, RN-BC, CHCP

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Finding the Patient Perspective: Molecular Testing in Advanced NSCLC

Educational Impact Challenge